This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients and its impact on cardiac surgery-induced kidney injury.
This study is to assess the benefits of goal-directed fluid management with ACUMEN in cardiac surgical patients undergoing a CABG, AVR, or CABG/AVR. Kidney injury biomarkers NGAL, Uromodulin, and Hepcidin-25 will be used to assess cardiac-induced kidney injury. Patients will be randomly enrolled in either standard care for fluid management or goal-directed fluid management with ACUMEN.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Enrollment
100
Fluid administration and hemodynamic management guided with the assistance of Edwards Lifesciences ACUMEN monitor
Acute Kidney Injury
KIDIGO Criteria for AKI
Time frame: 7 days or discharge whichever occurs first
Renal Biomarkers
NGAL, Hepcidin-25, and Uromodulin
Time frame: 48 hours postoperatively
Total Fluid Administered
intraoperative and postoperative volume given measured in milliliters
Time frame: From initiation of surgery to 48 hours postoperatively
ICU Length of Stay
Quantified in days and hours
Time frame: From admission to the intensive care unit until discharge or 20 weeks whichever comes first.
Hemodynamic Support Usage
Vasopressor or Inotrope usage
Time frame: During the first 48 hours postoperatively
Morbidity and Mortality
Death and Major adverse events (cerebral vascular stroke, myocardial infarction, infection, prolonged intubation \> 24 hours)
Time frame: 30 days
Blood Transfusions
Any Allogeneic Blood Transfusions
Time frame: From surgical incision to 48 hours postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.